Literature DB >> 9457313

Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells.

F A Ferrer1, L J Miller, R I Andrawis, S H Kurtzman, P C Albertsen, V P Laudone, D L Kreutzer.   

Abstract

OBJECTIVES: Recently, it was confirmed that angiogenesis is important in the development and spread of a variety of human cancers, including prostate cancer (PCa). Tumor neovascularization is thought to be controlled by chemical signals, known as angiogenic factors (AF). To date, little is known regarding the existence and role of AF in PCa. We previously reported on vascular endothelial growth factor (VEGF) in PCa. Currently, we compare VEGF expression with that of interleukin-8 (IL-8), another putative regulator of angiogenesis. We evaluated the expression of these two important AF in PCa and explored the role of inflammatory cytokines IL-1 and tumor necrosis factor (TNF) in their regulation.
METHODS: Ex vivo studies involved previously reported immunohistochemical analysis for VEGF and recent evaluation of IL-8 expression and distribution in archival tissue samples of PCa, benign prostatic hyperplasia (BPH), and normal prostate tissue. In vitro studies used PCa cells (DU-145) grown in culture and stimulated with cytokines thought to induce VEGF and IL-8 (ie, IL-1 alpha, IL-1 beta, TNF-alpha, and TNF-beta). After 24 hours, with or without cytokines, cell culture supernatants were analyzed by enzyme-linked immunosorbent assay or radioimmunoassay for VEGF or IL-8 levels.
RESULTS: Immunohistochemical studies of prostate tissue showed that PCa cells stained positively for VEGF and IL-8. Benign prostatic hyperplasia and normal prostate cells displayed little staining for either AF. Low levels of VEGF and IL-8 were produced by unstimulated DU-145 cells. Induction of DU-145 cells with cytokines resulted in differential stimulation whereby TNF was the predominant inducer of VEGF, whereas IL-1 was the predominant inducer of IL-8.
CONCLUSIONS: Our results indicate that significant levels of VEGF and IL-8 are present in PCa, but not BPH or normal prostate cells in vivo. In vitro studies suggest that differential regulation of AF expression occurs in PCa. Because IL-1 and TNF are present in the PCa tumor microenvironment, it is likely that differential regulation of AF also occurs in human PCa and contributes to differential tumor growth and metastasis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9457313     DOI: 10.1016/s0090-4295(97)00491-3

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  53 in total

1.  Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.

Authors:  Philip J Saylor; Kevin R Kozak; Matthew R Smith; Marek A Ancukiewicz; Jason A Efstathiou; Anthony L Zietman; Rakesh K Jain; Dan G Duda
Journal:  Oncologist       Date:  2012-02-02

2.  The picture of the prostatic lymphokine network is becoming increasingly complex.

Authors:  Georg E Steiner; Bob Djavan; Gero Kramer; Alessandra Handisurya; Martin Newman; Chung Lee; Michael Marberger
Journal:  Rev Urol       Date:  2002

3.  Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice.

Authors:  S J Kim; H Uehara; T Karashima; M Mccarty; N Shih; I J Fidler
Journal:  Neoplasia       Date:  2001 Jan-Feb       Impact factor: 5.715

4.  Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia.

Authors:  D Giri; M Ittmann
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

5.  Celastrol, an active constituent of the TCM plant Tripterygium wilfordii Hook.f., inhibits prostate cancer bone metastasis.

Authors:  K Kuchta; Y Xiang; S Huang; Y Tang; X Peng; X Wang; Y Zhu; J Li; J Xu; Z Lin; T Pan
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-02-14       Impact factor: 5.554

6.  Endothelial cells support the growth of prostate tissue in vivo.

Authors:  Michael Bates; Bruce Kovalenko; E Lynette Wilson; David Moscatelli
Journal:  Prostate       Date:  2008-06-01       Impact factor: 4.104

7.  Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.

Authors:  Jinlu Dai; Honglai Zhang; Andreas Karatsinides; Jill M Keller; Kenneth M Kozloff; Dana T Aftab; Frauke Schimmoller; Evan T Keller
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

8.  Targeted knockdown of EGR-1 inhibits IL-8 production and IL-8-mediated invasion of prostate cancer cells through suppressing EGR-1/NF-kappaB synergy.

Authors:  Jiajia Ma; Zijia Ren; Yang Ma; Lu Xu; Ying Zhao; Chaogu Zheng; Yinghui Fang; Ting Xue; Baolin Sun; Weihua Xiao
Journal:  J Biol Chem       Date:  2009-10-16       Impact factor: 5.157

9.  Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma.

Authors:  Suyun Huang; Lisa Mills; Badar Mian; Carmen Tellez; Marya McCarty; X-D Yang; Jean M Gudas; Menashe Bar-Eli
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

10.  The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy.

Authors:  Xinjie Lu; Dong Lu; Mike Scully; Vijay Kakkar
Journal:  Perspect Medicin Chem       Date:  2008-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.